Eritrodisestesia palmoplantarprevención con frío local

Referencias bibliográficas

• Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantarerythrodysesthesia (‘hand-foot’) syndrome: incidence, recognition and manage-ment. Am J Clin Dermatol 2000; 1: 225-234.
• Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysest-hesia syndrome. Ann Intern Med 1984; 101: 798-799.
• Comandone A, Bretti S, La Grotta G, et al. Palmar-plantar erythrodysesthesiasyndrome associated with 5-fluorouracil treatment. Anticancer Res 1993; 13:1781–1783.
• Ellis GK, Livingstone RB, Gralow JR, et al. Dose-dense anthracycline-basedchemotherapy for node-positive breast cancer. J Clin Oncol 2002; 20:3637–3643.
• Caeylx (pegylated liposomal doxorubicin). Product information, Schering-Plough Corporation; 2006.
• Jacobi U, Waibler E, Schulze P, et al. Release of doxorubicin in sweat: first stepto induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210–1211.
• Zuehlke KL. Erythematous eruption of palms and roles associated with mitota-ne therapy. Dermatologica 1974; 148: 90–92.
• Bhasin S, Sunita, Gupta DK et al. Chemotherapy-induced palmer plantererythrodysesthesia. J Assoc Physicians India 2005; 53: 155–156.
• Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-indiced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002; 16:31–37.
• Abeloff MD, Armitage JO, Niederhuber JE, et al. Clinical oncology. 3rd ed.Philadelphia (PA): Churchill Livingstone; 2004.
• Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am AcadDermatol 1991;24:457–61.
• Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacoki-netics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcino-ma. Cancer 2000;89:1037–47.
• Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndromeinduced by capecitabine. J Oncol Pharm Pract 2006;12:131-41.
• Esteve E, Schillio Y, Vaillant L, Bensaid P, Missonnier F,Metman EH. Efficacitéde la corticothérapie séquentielle dans un cas d’érythème acral douloureuxsecondaire au 5-fluoro-uracile à fortes doses. Ann Med Interne (Paris)1995;146:192-3.
• Komamura H, Higashiyama M, Hashimoto K, Takeda K, Kimura H, Tani Y.Three cases of chemotherapy-induced acral erythema. J Dermatol1995;22:116-21.
• Titgan MA. Prevention of palmar-plantar erythrodysesthesia associated withliposome-encapsulated doxorubicin (Doxil) by oral dexamethasone. Proc AmSoc Clin Oncol 1997;16:82a (Abstr. 288).
• Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989;111:688-9.
• Nagore E, Sánchez-Motilla JM, Insa A, Febrer MI. Síndrome de eritrodiseste-sia palmo-plantar por 5-fluorouracilo: respuesta favorable al tratamiento conpiridoxina. Med Cutan Iber Lat Am 1998;26:35-8.
• López AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSOtreatment for pegylated liposomal doxorubicin-induced palmar-plantar eryth-rodysesthesia. Cancer Chemother Pharmacol 1999;44:303-6.
• Kara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to doceta-xel-capecitabine therapy is treated with vitamin E without dose reduction.Breast 2006;15:414-24.
• Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am AcadDermatol 1991;24:457-61.
• Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions tochemotherapy. J Am Acad Dermatol 1999;40:367-98.
• Zimmerman GC, Keeling JH, Lowry M, Medina J, Von Hoff DD, Burris HA.Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. JNatl Cancer Inst 1994;86:557.
• Molpus KL, Anderson LB, Craig CL, Puleo JG. The effect of regional coolingon toxicity associated with intravenous infusion of pegylated liposomal doxoru-bicin in recurrent ovarian carcinoma. Gynecol Oncol 2004;93:513-6.
• Mangili G, Petrone M, Gentile C, et al. Prevention strategies in palmar–plan-tar erythrodysesthesia onset:The role of regional cooling. GynecologicOncology 108 (2008) 332-335.